Locally advanced basal cell carcinoma: vismodegib shows 85% response rate after discontinuation and relapse

  • Herms F & al.
  • J Clin Oncol
  • 14 Oct 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with locally advanced basal cell carcinoma (LA-BCC) who discontinued vismodegib and relapsed, retreatment is associated with an 85% objective response rate, according to a retrospective study.

Why this matters

  • Adverse events associated with vismodegib often lead to discontinuation.

Key results

  • Median relapse-free survival (RFS) of patients who discontinued vismodegib was 18.4 (95% CI, 13.5-24.8) months; 36-month RFS was 35.4% (95% CI, 22.5%-47.9%).
  • Limb/trunk BCC was associated with increased risk for relapse (HR, 2.77; P=.019).
  • 50% of patients who experienced relapse were retreated with vismodegib, with an objective response rate of 85% (37% complete response, 48% partial response) and eligibility for surgery in 42%.

Study design

  • 116 patients with LA-BCC who originally experienced a complete response with vismodegib but then discontinued were analyzed for RFS and effects of subsequent treatment.
  • 27 patients who experienced relapse were retreated with vismodegib.
  • Funding: Roche Laboratories.

Limitations

  • Retrospective study design.
  • Small patient sample size.